Axial Length

Axial length refers to the fundamental biometric measurement of the length along the primary axis of an anatomical structure. This measurement is crucial across various biological systems, influencing function, development, and overall health. In the context of human health, understanding axial dimensions is particularly significant for assessing the size and morphology of organs, with implications for a wide range of physiological processes and disease states.

Biological Basis

The axial length of organs and structures, such as the heart, is a complex trait influenced by both genetic and environmental factors. During development, intricate biological pathways and growth factors regulate cell proliferation and differentiation, ultimately determining the final dimensions of these structures. Genetic factors play a substantial role in this process, contributing to the observed variability in axial lengths among individuals. For instance, studies have shown moderate to high heritability for various echocardiographic traits, including a 52% heritability for aortic root dimension, 36–40% for left ventricular mass and internal dimensions, and 25% for left atrial size. ^[1] This indicates a significant genetic component underlying these axial measurements, suggesting that inherited genetic variations can influence the size and shape of cardiac structures.

Clinical Relevance

Measuring axial length is a vital tool in clinical diagnostics and monitoring, particularly in cardiovascular medicine. Echocardiography, for example, provides detailed assessments of cardiac dimensions, including left ventricular diastolic and systolic dimensions, left atrial diameter, and aortic root diameter. ^[1] These measurements, which represent different axial lengths of heart chambers and major vessels, are critical for diagnosing conditions such as cardiac remodeling, hypertrophic cardiomyopathy, and valvular heart disease. Deviations from normal axial lengths can indicate underlying pathology or increased risk for cardiovascular events. Furthermore, the genetic underpinnings of these dimensions are explored through genome-wide association studies (GWAS), which identify specific genetic variants associated with these traits. ^[1] Such research links these axial measurements to broader cardiovascular health indicators, including subclinical atherosclerosis, which encompasses measures like carotid intimal medial thickness (IMT) and coronary artery calcification. ^[2]

The social importance of understanding axial length, especially in relation to cardiovascular health, lies in its potential to improve public health outcomes. By identifying genetic factors that influence these fundamental dimensions, researchers can contribute to better risk stratification for common diseases. Early detection of structural abnormalities through these measurements can lead to timely interventions, potentially preventing severe complications. From a public health perspective, unraveling the genetic architecture of axial dimensions could pave the way for personalized medicine approaches, where an individual's genetic profile informs their risk assessment and guides tailored prevention and treatment strategies for cardiovascular diseases.

Methodological and Statistical Constraints

Studies on complex traits like axial length are often constrained by the statistical power available to detect genetic effects of modest size, particularly when accounting for the extensive multiple testing inherent in genome-wide association studies (GWAS). ^[1] While there may be adequate power for associations explaining a larger proportion of phenotypic variation, smaller yet biologically significant genetic influences may remain undetected, meaning that the absence of a statistically significant finding does not necessarily rule out a genetic role for a given single nucleotide polymorphism (SNP) or gene in influencing axial length. ^[1] Furthermore, some observed associations, despite appearing moderately strong, may represent false-positive results, necessitating rigorous replication in independent cohorts for validation . ^{[1], [3]}

The genetic arrays utilized in these investigations, such as the Affymetrix 100K GeneChip, provided only partial coverage of genetic variation across the human genome, potentially leading to missed associations due to insufficient SNP density within critical gene regions . ^{[1], [2], [4]} This limited coverage also poses challenges for replicating previously reported findings, as different studies might identify distinct SNPs in strong linkage disequilibrium with an unknown causal variant, resulting in apparent non-replication at the SNP level. ^[5] The inability to fully capture all genetic variation means that the current studies may not comprehensively characterize the genetic landscape influencing axial length. ^[4]

Phenotypic Characterization and Generalizability

Characterizing a dynamic trait like axial length by averaging observations across multiple examinations, especially over long periods such as two decades, introduces several complexities. ^[1] While this approach aims to reduce regression dilution bias and better represent the phenotype over time, it implicitly assumes that similar genetic and environmental factors influence the trait consistently across a broad age range, which may not be true and could mask age-dependent gene effects. ^[1] Additionally, the use of different diagnostic equipment over such extended periods could introduce misclassification or measurement error, impacting the accuracy and comparability of the phenotypic data. ^[1]

A significant limitation stems from the demographic composition of the study cohorts, which are often predominantly of white European descent. ^[1] This lack of diversity restricts the generalizability of the findings to other ethnic and ancestral populations, as genetic architectures and allele frequencies can vary substantially across different groups. Consequently, genetic associations identified for axial length in one population may not be directly transferable or reproducible in others, highlighting the critical need for broader inclusion of diverse cohorts to ensure global applicability of genetic insights. ^[1]

Unaccounted Genetic and Environmental Influences

The current analyses typically do not incorporate a comprehensive investigation of gene-environment interactions, which are crucial for understanding the full etiology of complex traits like axial length. ^[1] Genetic variants may influence phenotypes in a context-specific manner, with their effects being modulated by various environmental factors such as lifestyle, diet, or other external influences. ^[1] The omission of such analyses means that important context-dependent genetic effects remain undetected, presenting a significant knowledge gap in fully elucidating the genetic underpinnings of axial length. ^[1]

Despite evidence of moderate to high heritability for many quantitative traits, including those similar to axial length, the identified genetic variants often explain only a fraction of this heritable component . ^{[1], [2]} This phenomenon, often referred to as "missing heritability," suggests that numerous other genetic factors, such as rare variants, structural variations, or complex epistatic interactions, contribute to the trait but are yet to be discovered or fully understood by current GWAS methodologies. Furthermore, even for identified associations, the precise functional mechanisms through which these genetic variants influence axial length are frequently unknown, underscoring the necessity for further functional validation and mechanistic studies beyond statistical association. ^[3]

Variants

Genetic variations play a crucial role in determining various physiological traits, including axial length, a key determinant of refractive error. Several genes and their associated single nucleotide polymorphisms (SNPs) have been implicated in pathways relevant to eye development, growth, and tissue remodeling. These include genes involved in cell-to-cell communication, developmental signaling, cell cycle regulation, and extracellular matrix integrity, all of which contribute to the precise control of ocular dimensions.

Genes involved in cell communication and developmental signaling are vital for the intricate process of eye formation and growth. _GJD2_ (Gap Junction Delta 2), which encodes Connexin 36, is essential for forming gap junctions that enable direct cell-to-cell communication. Variants such as *rs16959560* and *rs11073058* could modulate the efficiency of this communication, thereby influencing the coordinated cellular activities necessary for proper eye development and, consequently, axial length. The _WNT7B_ (Wnt Family Member 7B) gene is a critical component of the Wnt signaling pathway, which regulates cell proliferation, differentiation, and tissue patterning during embryonic development. A variant like *rs10453459* might alter _WNT7B_ expression or function, potentially impacting the precise growth trajectories of ocular tissues and influencing the final axial length of the eye. Similarly, _RSPO1_ (R-Spondin 1) acts as an enhancer of Wnt signaling, playing roles in stem cell maintenance and tissue regeneration, processes fundamental to the continuous remodeling and growth of the eye. The *rs4074961* variant could modulate _RSPO1_'s activity, thereby affecting the overall growth and structural integrity of the eye and potentially contributing to variations in axial length. ^[6]

Other variants are found in genes that regulate cell growth, proliferation, and structural integrity. The _ATP5F1CP1_ - _CDKN3_ locus includes _CDKN3_ (Cyclin Dependent Kinase Inhibitor 3), a gene known to regulate the cell cycle by inhibiting cyclin-dependent kinases. Variations like *rs10459508* could impact cell proliferation and differentiation rates within ocular tissues, particularly the sclera, which is crucial for determining axial length. ^[2] Proper cell cycle control is essential for the precise growth required for emmetropia, and dysregulation might contribute to excessive ocular elongation. The _TPRG1_ - _TP63_ region encompasses _TP63_, a transcription factor vital for the development and maintenance of epithelial tissues, including those in the eye. A variant like *rs6789327* might affect the development or regeneration of ocular epithelial cells, indirectly influencing the structural integrity and growth of the eye. Moreover, _ANKFN1_ (Ankyrin Repeat And FN3 Domain Containing 1), located near _RPL39P33_ (Ribosomal Protein L39 Pseudogene 33), contains ankyrin repeat domains often involved in protein-protein interactions and the assembly of cellular structures. The *rs151278468* variant could affect these interactions, potentially influencing the mechanical properties of ocular tissues or their response to growth signals, thus affecting axial length. ^[7]

Variants in genes related to neuronal signaling and tissue remodeling also contribute to axial length variation. _VIPR2_ (Vasoactive Intestinal Peptide Receptor 2) encodes a receptor for vasoactive intestinal peptide, a neuropeptide involved in various physiological processes, including circadian rhythms and neuronal signaling. Given the known influence of neuronal pathways and neuromodulators on ocular growth, the *rs141313179* variant could alter _VIPR2_ signaling, impacting the intricate mechanisms that regulate eye size. ^[4] _RASGRF1_ (RAS Protein Specific Guanine Nucleotide Releasing Factor 1) is important for neuronal plasticity and growth factor signaling. Its role in visual processing and neuronal development suggests that the *rs13380109* variant could influence the neural regulation of eye growth and emmetropization, thus affecting axial length. _LRRC4C_ (Leucine Rich Repeat Containing 4C) is involved in cell adhesion and synapse formation, essential processes for maintaining the structural integrity and function of the neural retina. Alterations due to *rs7936359* might affect retinal signaling or the biomechanical properties of the sclera, both of which are critical determinants of axial length. ^[8] Finally, _PRSS56_ (Serine Protease 56) encodes a serine protease, enzymes known for their roles in protein degradation and extracellular matrix remodeling. The *rs77311538* variant could influence the activity of this protease, thereby affecting the synthesis or degradation of collagen and other components of the scleral extracellular matrix, a crucial factor in the regulation of axial length and the development of refractive errors.

Key Variants

RS ID	Gene	Related Traits
rs16959560 rs11073058	LINC02252 - GJD2	axial length measurement
rs10453459	WNT7B	axial length measurement
rs151278468	ANKFN1 - RPL39P33	axial length measurement
rs141313179	VIPR2	axial length measurement
rs13380109	RASGRF1	Hypermetropia axial length measurement
rs7936359	LRRC4C	axial length measurement
rs77311538	PRSS56	axial length measurement
rs6789327	TPRG1 - TP63	axial length measurement
rs10459508	ATP5F1CP1 - CDKN3	axial length measurement
rs4074961	RSPO1	axial length measurement intraocular pressure measurement corneal topography body height

Biological Background

The precise dimensions of biological structures, which can be broadly considered as forms of axial length, are fundamental to physiological function and are influenced by a complex interplay of genetic, cellular, and environmental factors. These dimensions, such as the size of cardiac chambers or the thickness of arterial walls, are crucial intermediate phenotypes that can reflect underlying health status and predict the risk of various diseases. ^[1] Understanding the biological mechanisms that regulate these dimensions provides insight into both normal physiological homeostasis and the pathogenesis of disease.

Genetic Regulation of Organ Dimensions

The dimensions of various organs are significantly heritable traits, indicating a strong genetic component influencing their size and structure. For instance, heritability estimates for cardiac dimensions like aortic root dimension and left ventricular mass are reported to be as high as 52% and 36-40%, respectively. ^[1] Genome-wide association studies (GWAS) have identified specific genetic loci and single nucleotide polymorphisms (SNPs) associated with these dimensions. For example, several SNPs, including rs10488825, rs10498091, and rs10514431, have been linked to left ventricular diastolic dimension and aortic root diameter. ^[1]

Beyond general associations, specific genes and their variants play critical roles in defining organ dimensions and their susceptibility to change. Genes such as angiotensinogen and angiotensin-converting enzyme (ACE) are involved in regulating cardiovascular hemodynamics and influencing left ventricular mass and function. ^[9] Other genes, including those for platelet-derived growth factor and vascular endothelial growth factor, have been implicated in vascular remodeling processes. ^[10] Furthermore, SNPs in or near genes like fibroblast growth factor (FGF1), adrenergic beta-2 receptor (ADRB2), myocyte enhancer factor 2C (MEF2C), thrombospondin 2 (THBS2), and cAMP-specific phosphodiesterase 4D (PDE4D) are associated with subclinical atherosclerosis phenotypes, which involve changes in arterial dimensions like carotid artery intima-media thickness (IMT) and calcification. ^[2] These genetic factors establish regulatory networks that govern the development and maintenance of organ size.

Cellular and Molecular Mechanisms of Tissue Remodeling

The precise dimensions of biological structures are maintained through intricate molecular and cellular pathways that regulate cell growth, differentiation, and extracellular matrix synthesis. When these pathways are disrupted, they can lead to significant changes in organ size and shape, often termed remodeling. For instance, left ventricular (LV) remodeling, characterized by changes in chamber size and wall thickness, is a key pathophysiological process in the development of high blood pressure and cardiovascular diseases. ^[1] This remodeling involves complex signaling pathways that mediate cellular responses to stress, such as chronic pressure overload.

Key biomolecules, including various growth factors, enzymes, and receptors, are central to these remodeling processes. Growth factors like platelet-derived growth factor and vascular endothelial growth factor modulate cellular proliferation and angiogenesis, critical for tissue maintenance and repair, but also implicated in pathological changes. ^[10] Enzymes such as angiotensin-converting enzyme (ACE) and HMG-CoA reductase (HMGCR) are crucial in metabolic and signaling cascades that influence cardiovascular structure and function. ^[11] Transcription factors like MEF2C directly regulate gene expression patterns that drive cellular changes in response to environmental cues or disease states, thereby impacting tissue architecture and dimensions. ^[2]

Physiological Regulation and Pathophysiological Processes

The maintenance of optimal organ dimensions is a critical aspect of physiological homeostasis, with disruptions often contributing to disease pathogenesis. For example, left ventricular chamber size and mass are fundamental in the development of hypertension, stroke, and heart failure. ^[1] Abnormalities in these dimensions can reflect underlying stress on the cardiovascular system and serve as markers of disease progression. Similarly, endothelial dysfunction, often assessed by brachial artery flow-mediated dilation, is a key precursor to atherosclerosis, a condition characterized by arterial wall thickening and hardening. ^[1]

Pathophysiological processes that alter tissue dimensions include inflammatory responses, metabolic imbalances, and structural damage. Subclinical atherosclerosis, involving carotid artery intima-media thickness and arterial calcification, represents a significant disruption in vascular homeostasis, leading to changes in arterial dimensions. ^[2] These processes often involve compensatory responses, such as cardiac hypertrophy (increase in heart muscle mass), which initially attempt to maintain function but can eventually become maladaptive, further exacerbating disease. The systemic consequences of these localized changes can contribute to widespread cardiovascular morbidity and mortality. ^[1]

Metabolic Factors and Biomolecular Interactions

Metabolic processes and the function of key biomolecules are intrinsically linked to the regulation of organ dimensions and overall physiological health. Metabolite profiles and lipid concentrations in human serum are heritable traits, and their variations can influence cardiovascular dimensions and disease risk. ^[12] For instance, HMGCR, an enzyme involved in cholesterol synthesis, has variants associated with LDL-cholesterol levels, impacting lipid metabolism which is a major factor in atherosclerosis. ^[13] Similarly, uric acid concentration is associated with the risk of gout and other metabolic conditions. ^[14]

Beyond metabolic intermediates, specific proteins serve as critical biomarkers or structural components that reflect or influence tissue dimensions. Osteocalcin, a protein involved in bone health, and C-reactive protein, an inflammatory marker, are examples of biomolecules whose levels are indicative of physiological states relevant to overall health. ^[15] These biomolecules interact within complex regulatory networks, where their levels and activities can signal physiological stress, inflammation, or metabolic dysregulation, all of which can ultimately affect the dimensions and integrity of various biological structures.

References

[1] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S2.

[2] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S4.

[3] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, 2007.

[4] Yang, Qiong et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S7.

[5] Sabatti, Chiara, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 41, no. 1, 2009, pp. 31–42. PubMed, PMID: 19060910.

[6] Wilk, J. B. et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Medical Genetics, vol. 8, 2007, p. S8.

[7] Wallace, Cathryn et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." The American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139–149.

[8] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, 2008.

[9] Tang, W., et al. "Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study." Am Heart J, vol. 143, 2002, pp. 854-860.

[10] Tambur, A. R., et al. "Genetic polymorphism in platelet-derived growth factor and vascular endothelial growth factor are significantly associated with cardiac allograft vasculopathy." J Heart Lung Transplant, vol. 25, 2006, pp. 690-698.

[11] Vasan, R. S., et al. "No association between ACE I/D polymorphism and cardiovascular hemodynamics during exercise in young women." Int J Sports Med, vol. 26, 2005, pp. 638-644.

[12] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genetics, vol. 4, no. 11, 2008, p. e1000282.

[13] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2008.

[14] Dehghan, A., et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, 2008.

[15] Gundberg, C. M., et al. "Osteocalcin: isolation, characterization, and detection." Methods Enzymol, vol. 107, 1984, pp. 516-544.